Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.

Anholm C, Kumarathurai P, Pedersen LR, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB

Diabetes, obesity & metabolism23 Feb 2017Cited by 18 (Europe PMC)

PMID28124822DOI10.1111/dom.12891PepBankPUB-28124822

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with stable coronary artery disease and newly diagnosed type 2 diabetes, liraglutide improved first phase insulin secretion (AIRg) about 3-fold.
In plain wordsIn patients with heart disease and new type 2 diabetes, liraglutide improved the first burst of insulin release after sugar.
Peptide
Liraglutide
Outcome
IncreaseFirst phase insulin secretion (AIRg)
Study
n = 30
Comparator
Placebo plus metformin
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide treatment improved AIRg by 3-fold, 497 mU × L^-1 × min (IQR 342; 626, P < .0001) and DI by 1-fold, 766 (SD 824, P < .0001).
3 context sentences(design, population, supporting numbers)
Summary · context
The design of the study was a randomized, double-blind, placebo-controlled, cross-over trial in patients with stable CAD and newly diagnosed well-controlled T2DM.
Summary · context
Patients were treated with liraglutide/metformin vs placebo/metformin for a 12 + 12-week period with ≥2-week wash-out.
Summary · context
A total of 30 patients from among 41 randomized were available for paired analysis.
Report a problemFND-2812482201
02HumanRandomized controlled trialEfficacy outcome
In patients with stable coronary artery disease and newly diagnosed type 2 diabetes, liraglutide improved the disposition index, a measure of beta-cell function.
In plain wordsIn patients with heart disease and new type 2 diabetes, liraglutide improved a measure of how well insulin-producing cells work.
Peptide
Liraglutide
Outcome
IncreaseDisposition index (DI)
Study
n = 30
Comparator
Placebo plus metformin
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide treatment improved AIRg by 3-fold, 497 mU × L^-1 × min (IQR 342; 626, P < .0001) and DI by 1-fold, 766 (SD 824, P < .0001).
3 context sentences(design, population, supporting numbers)
Summary · context
The design of the study was a randomized, double-blind, placebo-controlled, cross-over trial in patients with stable CAD and newly diagnosed well-controlled T2DM.
Summary · context
Patients were treated with liraglutide/metformin vs placebo/metformin for a 12 + 12-week period with ≥2-week wash-out.
Summary · context
A total of 30 patients from among 41 randomized were available for paired analysis.
Report a problemFND-2812482202
03HumanRandomized controlled trialEfficacy outcome
In patients with stable coronary artery disease and newly diagnosed type 2 diabetes, liraglutide treatment gave a significant weight loss of -2.7 kg.
In plain wordsIn patients with heart disease and new type 2 diabetes, liraglutide treatment led to weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 30
Comparator
Placebo plus metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Weight change
−2.7 kg
liraglutide
Source sentences
Summary
Despite a significant weight loss of -2.7 kg (-6.7; -0.6) during liraglutide treatment, we found no improvement in HOMA-IR, Si or Sg.
3 context sentences(design, population, supporting numbers)
Summary · context
The design of the study was a randomized, double-blind, placebo-controlled, cross-over trial in patients with stable CAD and newly diagnosed well-controlled T2DM.
Summary · context
Patients were treated with liraglutide/metformin vs placebo/metformin for a 12 + 12-week period with ≥2-week wash-out.
Summary · context
A total of 30 patients from among 41 randomized were available for paired analysis.
Report a problemFND-2812482203
04HumanRandomized controlled trialEfficacy outcome
In patients with stable coronary artery disease and newly diagnosed type 2 diabetes, liraglutide did not improve HOMA-IR.
In plain wordsIn patients with heart disease and new type 2 diabetes, liraglutide did not improve a score of insulin resistance.
Peptide
Liraglutide
Outcome
No significant changeHOMA-IR
Study
n = 30
Comparator
Placebo plus metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Despite a significant weight loss of -2.7 kg (-6.7; -0.6) during liraglutide treatment, we found no improvement in HOMA-IR, Si or Sg.
3 context sentences(design, population, supporting numbers)
Summary · context
The design of the study was a randomized, double-blind, placebo-controlled, cross-over trial in patients with stable CAD and newly diagnosed well-controlled T2DM.
Summary · context
Patients were treated with liraglutide/metformin vs placebo/metformin for a 12 + 12-week period with ≥2-week wash-out.
Summary · context
A total of 30 patients from among 41 randomized were available for paired analysis.
Report a problemFND-2812482204
05HumanRandomized controlled trialEfficacy outcome
In patients with stable coronary artery disease and newly diagnosed type 2 diabetes, liraglutide did not improve insulin sensitivity (Si).
In plain wordsIn patients with heart disease and new type 2 diabetes, liraglutide did not improve how well the body responds to insulin.
Peptide
Liraglutide
Outcome
No significant changeInsulin sensitivity (Si)
Study
n = 30
Comparator
Placebo plus metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Despite a significant weight loss of -2.7 kg (-6.7; -0.6) during liraglutide treatment, we found no improvement in HOMA-IR, Si or Sg.
3 context sentences(design, population, supporting numbers)
Summary · context
The design of the study was a randomized, double-blind, placebo-controlled, cross-over trial in patients with stable CAD and newly diagnosed well-controlled T2DM.
Summary · context
Patients were treated with liraglutide/metformin vs placebo/metformin for a 12 + 12-week period with ≥2-week wash-out.
Summary · context
A total of 30 patients from among 41 randomized were available for paired analysis.
Report a problemFND-2812482205
06HumanRandomized controlled trialEfficacy outcome
In patients with stable coronary artery disease and newly diagnosed type 2 diabetes, liraglutide did not improve glucose effectiveness (Sg).
In plain wordsIn patients with heart disease and new type 2 diabetes, liraglutide did not improve how well glucose clears itself from blood.
Peptide
Liraglutide
Outcome
No significant changeGlucose effectiveness (Sg)
Study
n = 30
Comparator
Placebo plus metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Despite a significant weight loss of -2.7 kg (-6.7; -0.6) during liraglutide treatment, we found no improvement in HOMA-IR, Si or Sg.
3 context sentences(design, population, supporting numbers)
Summary · context
The design of the study was a randomized, double-blind, placebo-controlled, cross-over trial in patients with stable CAD and newly diagnosed well-controlled T2DM.
Summary · context
Patients were treated with liraglutide/metformin vs placebo/metformin for a 12 + 12-week period with ≥2-week wash-out.
Summary · context
A total of 30 patients from among 41 randomized were available for paired analysis.
Report a problemFND-2812482206
07HumanRandomized controlled trialOther
In patients with stable coronary artery disease and newly diagnosed type 2 diabetes, weight loss during liraglutide therapy did not result in a carry-over effect.
In plain wordsIn patients with heart disease and new type 2 diabetes, weight loss during liraglutide treatment did not carry over into the next period.
Peptide
Liraglutide
Outcome
No significant changeCarry-over effect of weight loss
Study
n = 30
Comparator
Placebo plus metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Weight loss during liraglutide therapy did not result in a carry-over effect.
3 context sentences(design, population, supporting numbers)
Summary · context
The design of the study was a randomized, double-blind, placebo-controlled, cross-over trial in patients with stable CAD and newly diagnosed well-controlled T2DM.
Summary · context
Patients were treated with liraglutide/metformin vs placebo/metformin for a 12 + 12-week period with ≥2-week wash-out.
Summary · context
A total of 30 patients from among 41 randomized were available for paired analysis.
Report a problemFND-2812482207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords